Patent US10709673

Use of cannabinoids in the treatment of epilepsy
[+] Show Details

US10709673

1. An oral composition consisting of: (i) cannabidiol (CBD) at a concentration of between about 22.5 mg/ml and about 110 mg/ml, (ii) ethanol at a concentration of about 71.1 mg/ml to about 86.9 mg/ml, (iii) a sweetener at a concentration of about 0.45 mg/ml to about 0.55 mg/ml, (iv) a flavoring at a concentration of about 0.18 mg/ml to about 0.22 mg/ml, and (v) sesame oil q.s. to about 1.0 ml. (7) (0)

2. The composition of claim 1, wherein the CBD is at a concentration of about 25 mg/mL ±10%. (2) (0)

3. The composition of claim 1, wherein the CBD is at a concentration of about 100 mg/mL ±10%. (2) (0)

4. The composition of claim 1, wherein the CBD has a purity of at least about 95% (w/w). (0)

5. The composition of claim 1, wherein the CBD has a purity of at least about 98% (w/w). (0)

10. The composition of claim 1, wherein the sweetener is sucralose. (0)

11. The composition of claim 1, wherein the flavoring is strawberry flavoring. (0)

12. The composition of claim 1, wherein: (i) the CBD is at a concentration of between about 90 mg/ml and about 110 mg/ml; (ii) ethanol is at a concentration of about 71.1 mg/ml to about 86.9 mg/mL; (iii) the sweetener is at a concentration of about 0.45 mg/ml to about 0.55 mg/ml; (iv) the flavoring is at a concentration of about 0.18 mg/ml to about 0.22 mg/ml; and (v) the sesame oil, q.s. to about 1.0 ml. (4) (0)

18. An oral composition consisting of: (0) (5)

(i) CBD at a concentration of between about 90 mg/ml and about 110 mg/ml, wherein the CBD has a purity of at least about 95% (w/w);

(ii) ethanol at a concentration of about 71.1 mg/ml to about 86.9 mg/mL;

(iii) a sweetener at a concentration of about 0.45 mg/ml to about 0.55 mg/ml;

(iv) flavoring at a concentration of about 0.18 mg/ml to about 0.22 mg/ml; and

(v) sesame oil, q.s. to about 1.0 ml.

View Abstract and Specification Size

PDF with Images and Document Face >

Full Text Publication >

Patent US10709673

Use of cannabinoids in the treatment of epilepsy

Patent Matrix® Search